By Stefan Hyde, Automation Manager, Asahi Kasei Bioprocess America
New and innovative treatments and changing market dynamics have led to a dramatic shift in how drugs are developed and manufactured. For example, a focus on smaller patient populations means drugs must be produced in lower volumes, resulting in an increased focus on process intensification in upstream manufacturing. As antibody titers go up, though, the strain on downstream processing creates significant bottlenecks in the production of novel therapies.
Automation can help overcome these challenges by improving process control, which ultimately results in better productivity and consistency. However, many of the current automation software platforms are not designed for both the needs of industry as well as the people who will be using it. OCELOT System Control, a new automation software platform from Asahi Kasei Bioprocess America (AKBA), offers all the capabilities of its competitors but with a user-friendly platform that simplifies implementation and operation.